Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
Luminous enrolls first UK patient
CE Mark for Viscosurgical device
KalVista obtains series A funding
Fortified antibiotic agents for keratitis

Survey

Do you think plasma kallikrein inhibitors are the way forward in the treatment of DME?

Click here to vote

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.

Click here to contact Neil Hanley, sales manager.

August 31, 2011
First UK patient enrolled onto Novartis retinal vascular disease study
Luminous, a program created to develop the understanding of retinal vascular diseases, has enrolled its first patient this month. More...
AMO ophthalmic viscosurgical device obtains CE Mark of Approval
Abbott Medical Optics' Healon EndoCoat has received the European CE Mark of approval. More...
Vienna Guide
Continuing Ophthalmology Times Europe's series of City Guides, seeingVienna, sponsored by Oertli, will help you get the most out of your stay. To read more please click here
DME firm raises £8 million in series A funding
New ophthalmic company KalVista Pharmaceuticals has generated £8 million from series A contributed by Novo A/S and SV Life Sciences. More...
Fortified antibiotic agents are needed for the management of keratitis
An investigation in the Journal of Cataract and Refractive Surgery strongly suggests the use of fortified antibiotic agents for prevention of vision loss in infectious keratitis patients. More...

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone
numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other
opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, please contact us by emailing [email protected] or by mail
at Advanstar Communications Inc., Bridgegate Pavilion, 4A Chester Business Park, Wrexham Road, Chester, CH4 9QH. United Kingdom